# Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

> **NCT02537574** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 380 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** NTX/BUP
- **DRUG:** NTX/PBO-B
- **DRUG:** PBO-N/PBO-B

## Key facts

- **NCT ID:** NCT02537574
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-10-27
- **Final completion:** 2017-01-09
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02537574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02537574, "Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02537574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*